Med-tech financing activity rebounded sharply in 2025, with total reported capital raised climbing to $39.55 billion, nearly ...

Jun Chen, a tenured associate professor of bioengineering at the Samueli School of Engineering at the University of ...

Incregen Therapeutics LLC has advanced INC-118, a glucose-dependent insulinotropic polypeptide (GIP) ligand antagonist ...

Immorta Bio Inc. has reported new data demonstrating that its combination therapy of Senovax, a first-in-class senolytic ...

Ukko Inc. has announced plans to initiate clinical trials with UKK-0018 for peanut allergy in the first half of this year.

And another firm has reached a most-favored nation (MFN) pricing deal with the White House. Johnson & Johnson announced Jan. 8 a voluntary agreement with the Trump administration aimed at improving ...

Generative AI has largely escaped the U.S. FDA’s regulatory purview up to now, but OpenAI seems poised to create a new source of regulatory angst for the agency. The company unveiled its ChatGPT ...

Investors poured a further $13 million into Vicentra BV for Kaleido, its insulin patch pump system, taking the total raised in the company’s series D financing round to $98 million. The funds come ...

Annual biopharma financing values have fluctuated significantly over the past seven years, peaking during the pandemic-era surge in 2020 and 2021 before retreating in 2022. After rebounding to more ...

Hisamitsu Pharmaceutical Co. Inc. President and CEO Kazuhide Nakatomi is leading a management buyout to take the company private, citing mounting drug pricing pressures and tougher listing ...

Ollin Biosciences Inc. is gearing up for global phase III trials this year after disclosing favorable top-line results from its randomized, head-to-head phase Ib Jade study comparing OLN-324, a ...

Human respiratory syncytial virus (hRSV) represents a major global health burden and is a leading cause of severe respiratory disease, particularly among preterm infants. Despite extensive efforts to ...